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ResectionAbstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene ho-
mologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves out-
comes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI
[folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these
combinations.
Methods: Multicentre, open-label study in untreated patients  18 years with (WT)-KRAS
mCRC and multiple or unresectable liver-limited disease (LLD) randomised to either
Pmab-FOLFOX4 or Pmab-FOLFIRI. The primary end-point was objective response rate
(ORR). Secondary end-points included liver metastases resection rate (R0 þ R1),
progression-free survival (PFS), overall survival (OS), adverse events and perioperative safety.
Exploratory end-points were: response by RAS status, early tumour shrinkage (ETS) and
depth of response (DpR) in WT-RAS patients.
Results: Data on 77 patients were analysed (38 Pmab-FOLFOX4; 39 Pmab-FOLFIRI; WT-
RAS: 27/26, respectively). ORR was 74% with Pmab-FOLFOX4 and 67% with Pmab-
FOLFIRI (WT-RAS: 78%/73%). Out of the above, 45% and 59% underwent surgical resec-
tion, respectively (WT-RAS: 37%/69%). The R0-R1 resection rate was 34%/46% (WT-
RAS:26%/54%). Median PFS was 13/14 months (hazard ratio [HR] Pmab-FOLFIRI versus
Pmab-FOLFOX4: 0.9; 95% confidence interval: [0.6e1.5]; WT-RAS:13/15; HR: 0.7 [0.4
e1.3]). Median OS was 37/41 months (HR:1.0 [0.6e1.8]; WT-RAS: 39/49; HR:0.9 [0.4
e1.9]). In WT-RAS patients with confirmed response, median DpR was 71%/66%, and
65%/77% of patients showed ETS  30%/  20% at week 8, without significant differences be-
tween arms; these patients had longer median PFS and OS and higher resectability rates. Sur-
gery was associated with longer survival. Perioperative and overall safety were similar, except
for higher grade 3/4 neutropenia (40%/10%; pZ 0.003) and neuropathy (13%/0%; pZ 0.025)
in the Pmab-FOLFOX4 arm.
Conclusions: In patients with WT-KRAS mCRC and LLD, both first-line Pmab-FOLFOX4
and Pmab-FOLFIRI resulted in high ORR and ETS, allowing potentially curative resection.
No significant differences in efficacy were observed between the two regimens.
(clinicaltrials.gov:NCT00885885).
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The addition of epidermal growth factor receptor
(EGFR)-targeted therapies to chemotherapy for the
first-line treatment of wild-type (WT) RAS metastatic
colorectal cancer (mCRC) has improved patient’s
objective response rate (ORR), progression-free survival
(PFS) and overall survival (OS) [1e4]. For this reason,
current guidelines recommend their use in combination
with the most common backbone chemotherapeutic
regimens such as FOLFOX [folinic acid, 5-fluorouracil,
and oxaliplatin] or FOLFIRI [folinic acid, 5-
fluorouracil, and irinotecan] [5,6].
In mCRC patients with liver-limited disease (LLD),
resection of liver metastasis is the main objective. An OS
rate of up to 45% at 5 years, and a median OS of 52
months has been reported [7]. However, 80e90% of liver
metastases are unresectable due to size, location, extent
of disease or remnant liver.
Conversion chemotherapy can increase the resect-
ability rate [8]. After oxaliplatin-based chemotherapy,
14e51% of unresectable patients were subjected tosurgery, with 5-year OS rates (34e50%) similar to those
from initially resectable patients [9,10]. The addition of
anti-EGFR agents increases the ORR to 45% and the
resection rate to 28e30% [11e15].
Panitumumab (Pmab) has demonstrated efficacy and
a manageable safety profile in WT-KRAS (exon 2)
mCRC patients, either as a monotherapy [16e19] or in
combination with first-line FOLFOX4 [19] or FOLFIRI
[4] or second-line FOLFIRI [20].
Mutant KRAS (exon 2) predicts a lack of response to
anti-EGFR agents, and may also be a factor for
chemotherapy resistance [21], better established for iri-
notecan than for oxaliplatin. Recently, other activating
mutations for the members of the RAS oncogene family,
KRAS and NRAS, were confirmed to predict a lack of
response to Pmab, leading to a label variation [1].
Nevertheless, there are still one quarter of WT-RAS
patients that are non-responders as defined by the
Response Evaluation Criteria in Solid Tumours
(RECIST) [22]. Several assessments beyond RECIST
may help in predicting OS, such as timing, depth, and
duration of response (DoR). Early tumour shrinkage
A. Carrato et al. / European Journal of Cancer 81 (2017) 191e202 193(ETS) of 20% or 30% at weeks 6e8 predicts
improved PFS and OS [23e26]. Other clinical benefits of
early and deep responses may include symptomatic relief
and improved resectability [25].
Our aim was to evaluate the efficacy and safety of the
addition of Pmab to FOLFOX4 (Pmab-FOLFOX4) or
FOLFIRI (Pmab-FOLFIRI) as a first-line treatment for
WT-KRAS (exon 2) mCRC patients with LLD. We also
explored differences in outcomes according to RAS
status (exons 2, 3, 4 of KRAS/NRAS ) and investigated
tumour assessments beyond RECIST in the WT-RAS
population, including ETS and DpR.
2. Patients and methods (see extended version in
Appendix)
2.1. Study design
This phase II, open-label, randomised (1:1), multicentre,
two-arm parallel study was conducted in 15 Spanish
centres. Patients were included between May 2009 and
November 2012. All patients provided written informed
consent.
2.2. Patients
Inclusion criteria were: (1) age  18 years; (2) histologi-
cally confirmed WT-KRAS (exon 2) mCRC untreated
patients; (3) multiple (>4 liver metastasis or any liver
metastasis longer than 10 cm) or unresectable LLD
considered by the local hepatic surgeons’ criteria; (4) at
least one unidimensionally measurable lesion according
to the modified response evaluation criteria in solid tu-
mours (mRECIST); (5) recurrence after adjuvant treat-
ment with 5-fluorouracil/folinic acid or capecitabine with
or without radiotherapy with a disease-free interval
(DFI) > 6 months, or with an oxaliplatin-based regimen
with a DFI > 12 months, or recurrence after surgical
treatment and/or radiotherapywithout adjuvant systemic
treatment or de novo diagnosis; (6) Karnofsky perfor-
mance status  70%; and (7) adequate bone marrow,
hepatic and renal function and magnesium levels.
Main exclusion criteria were: hormonal-, chemo-,
immunotherapy, experimental or approved proteins/
antibodies (e.g. bevacizumab) received for mCRC; sur-
gery and/or radiotherapy in the previous 4 weeks.
2.3. Study treatment
Patients were randomised to either Pmab-FOLFOX4 or
Pmab-FOLFIRI. Pmab (6 mg/kg) was administered
with FOLFOX4 or FOLFIRI every 14 ds for 4e8 cy-
cles. When surgery became an option, it was performed
4e6 weeks after the last chemotherapy dose. Patients
with stable disease or who did not achieve resectability
received additional cycles until progressive disease (PD),
unacceptable toxicity or patient withdrawal. In the eventof successful resection, six cycles of adjuvant treatment
(similar to presurgery) were administered starting 4e8
weeks after surgery.
2.4. Study procedures
Tumour response was determined by mRECIST criteria
every 8  1 weeks until PD or patient withdrawal.
Resectability was assessed every 2 months.
2.5. Statistical analysis
Primary end-point: ORR (complete response þ partial
response). Secondary end-points: resection rate
(R0 þ R1) of liver metastases, time to resection, PFS,
OS, adverse events (AEs) and perioperative safety.
Exploratory end-points: response according to RAS
status, ETS and DpR in the WT-RAS population, and
their relationship with PFS, OS and surgical resection.
Considering a minimum ORR of 30%, a sample of 40
subjects per arm was required for correctly
selecting better treatment when the superior arm was
10% higher, with at least 80% probability (Simon-
Wittes-Ellenberg design).
The analysis set included all patients who received at
least one dose of Pmab or chemotherapy and were fol-
lowed up to 31st March 2015. Efficacy end-points were
reported using descriptive statistics, 95% confidence in-
tervals (CI), and KaplaneMeier plots. Results of un-
confirmed response are reported because liver
metastases resection was performed in some patients
before radiological response confirmation.
Data analysis was performed using the SAS statis-
tical package for Windows (v9.4, SAS Institute Inc.,
Cary, U.S.).
3. Results
3.1. Patients’ characteristics
The study included 77 patients (38 received Pmab-
FOLFOX4 and 39 received Pmab-FOLFIRI) with
WT-KRAS mCRC (Fig. 1). The RAS status was deter-
mined in 83% of the WT-KRAS patients, of which 83%
were WT-RAS (exons 2, 3, 4 [KRAS]; exons 2, 3, 4
[NRAS]). No double mutations were observed. Baseline
characteristics were similar between arms except for a
numerically higher proportion of WT-RAS patients with
technically resectable metastases in the Pmab-FOLFIRI
arm (Table 1).
3.2. Treatment
In both arms, patients received a median of eight in-
fusions of Pmab (range: 1e80) (Table 2) and achieved a
median presurgery absolute intensity dose of 5.2 mg/kg/
week (range: 2.6e6.1). Some 64% of patients received
Assessed for eligibility (N=103) 
Excluded (N=23) 
♦ Not meeting inclusion criteria (N= 21) 
♦ Meeting exclusion criteria (N= 2)
RAS ascertainment (N= 31) 
Allocated to panitumumab + FOLFOX4 (N=40) 
- Received intervention (N=38) 
- Did not received allocated intervention (N=2*) 
• Reasons: 
- Received panitumumab + FOLFIRI: 2 
Discontinued intervention (N=39): 
- Death: 2 
- Non-acceptable toxicity: 2 
- Non-related AE: 1 
- Disease progression: 11 
- Investigator decision: 9 
- Protocol non-compliance: 0 
- Treatment completed: 10 
- Other reason: 4 
Allocated to panitumumab + FOLFIRI (N=40) 
- Received intervention (N=39*)
− Did not receive allocated intervention (N=3)  
• Reasons: 
- Divergent KRAS results: 1  
- Metastases in locations other than liver: 2
Randomized (N=80) 
WT-KRAS
population (N=77)
RAS ascertainment (N= 33) 
WT-RAS population (N=53)WT-RAS
(N=27)
Mutant RAS
(N=4)
WT-RAS
(N=26)
Mutant RAS
(N=7)
WT-KRAS analysed (N= 39) 
  - Excluded from analysis (N=3): 
•Reason:  
- Did not receive allocated intervention: 3
WT-KRAS analysed (N=38)  
Discontinued intervention (N=38): 
- Non-acceptable toxicity: 7 
- Non-related AE: 1 
- Disease progression: 13 
- Investigator decision: 3 
- Protocol non-compliance: 1 
- Treatment completed: 10 
- Other reason: 3 
*Two patients allocated to panitumumab + FOLFOX4 arm received panitumumab + FOLFIRI  by error. 
WT: wild type; AE: adverse event
Fig. 1. Study flow-chart.
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received  90%).
Dose reductions and delays were slightly higher in the
Pmab-FOLFOX4 arm, leading to a lower median rela-
tive dose-intensity (Table 2).3.3. Efficacy in the WT-KRAS population
UnconfirmedORRwas noted in 70%of the patients (74%
(95% CI: 60e88) with Pmab-FOLFOX4 and in 67%
(52e82) with Pmab-FOLFIRI) (Table 3, Supplemental
Table 1
Patient characteristics at baseline in the WT-KRAS population and in the WT-RAS population.
WT-KRAS Population WT-RAS Population
Pmab-FOLFOX4 Pmab-FOLFIRI Pmab-FOLFOX4 Pmab-FOLFIRI
(N Z 38) (N Z 39) (N Z 27) (N Z 26)
Male, n (%) 31 (82) 28 (72) 23 (85) 18 (69)
Median age, years (min, max) 65 (32, 79) 63 (37, 83) 65 (32, 79) 60 (37, 78)
Median time since CRC diagnosis, months (Q1, Q3) 3.4 (1.3, 22.7) 1.6 (0.6, 11.5) 3.1 (1.5, 21.0) 1.6 (0.5, 27.0)
Technically resectable liver metastases, n (%) 12 (32) 12 (31) 5 (19) 9 (35)
Primary tumour diagnosis, n (%)
Colon 28 (74) 27 (69) 19 (70) 16 (62)
Rectum 9 (24) 11 (28) 7 (26) 9 (35)
Colon and rectum 1 (3) 1 (3) 1 (4) 1 (4)
TNM stage at diagnosis
I 1 (3) 2 (5) 0 1 (4)
II 0 1 (3) 0 1 (4)
III 5 (13) 3 (8) 4 (15) 2 (8)
IV 32 (84) 32 (82) 23 (85) 22 (85)
Prior surgery for primary tumour, n (%) 26 (68) 22 (56) 19 (70) 15 (58)
Prior adjuvant/neoadjuvant CT and/or radiotherapy, n (%) 6 (16) 4 (10) 4 (15) 3 (12)
Prior FOLFOX, n (%) 3 (8) 3 (8) 2 (7) 3 (12)
CRC Z colorectal cancer; CT Z chemotherapy; Pmab Z panitumumab; WT Z wild-type.
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months (95% CI: 4.2e6.9) and 4.2 months (95% CI:
3.9e6.7), respectively, without differences between arms
(HR Pmab-FOLFIRI versus Pmab-FOLFOX4: 1.1; 95%
CI: 0.5e2.3; pZ 0.853).
After preoperative treatment, some 52% of the pa-
tients underwent surgical resection of liver metastases
(45% of the Pmab-FOLFOX4 treatment arm and 59%
of the Pmab-FOLFIRI) (Table 3). In the subgroup with
unresectable metastases, resection was possible in 27%
and 50% of patients, respectively. The (R0 þ R1)
resection rate was 34% and 46%. Median time to
resection was 7.8 months and 6.2 months, withoutTable 2
Treatment exposure in the WT-KRAS population.
Pmab-FOLFOX4 Pmab-FOLFIRI
(N Z 38) (N Z 39)
Pre-surgery
Median Pmab doses per
patient (min, max)
8 (2, 80) 8 (1, 30)
Median CT doses per
patient (min, max)
8.5 (2, 81) 8 (1, 31)
Median relative dose-intensity
for Pmab, % (Q1, Q3)
80 (73, 93) 88 (81, 96)
Median relative dose-intensity
for CT, % (Q1, Q3)
83 (64, 92) 89 (78, 94)
Post-surgery
Median Pmab doses per
patient (min, max)
6 (1, 22) 6 (1, 8)
Median CT doses per patient
(min, max)
6 (1, 16) 6 (1, 9)
Median relative dose-intensity
for Pmab, % (Q1, Q3)
91 (78, 96) 89 (78, 98)
Median relative dose-intensity
for CT, % (Q1, Q3)
78 (69, 89) 94 (84, 100)
CT Z chemotherapy; Pmab Z panitumumab.significant differences between arms (HR: 1.4; 95% CI:
0.8e2.6; p Z 0.284). Median time to recurrence in pa-
tients with R0 or R1 was 11 months and 9 months,
respectively.
After a median follow-up of 33 months (range:
1.4e64.0), median PFS was 13 months with Pmab-
FOLFOX4 and 14 months with Pmab-FOLFIRI
(p Z 0.730) (Fig. 2). Median OS was 37 months and 41
months, respectively (pZ 0.966) (Fig. 2).
3.4. Efficacy according to RAS status
In patients with WT-RAS, the unconfirmed ORR
increased to 76%, without differences between arms
(Table 3, Supplemental Fig. S1 (online only)).
After preoperative treatment, some 53% of WT-RAS
subgroup of patients underwent surgical resection. In
the subgroup with unresectable metastases (n Z 39),
surgical resection was possible in 54% of patients.
The (R0 þ R1) resection rate in the WT-RAS sub-
group was 40% (32% R0; 8% R1).
Median PFS in WT-RAS patients was 13 months
with Pmab-FOLFOX4 and 15 months with Pmab-
FOLFIRI (Fig. 2). Median OS was 39 and 49 months,
respectively (Fig. 2).
3.5. Depth of response in the WT-RAS population
Median DpR was 48% (Q1-Q3: 32e67%), without dif-
ferences between arms. In patients with radiologically
confirmed response (n Z 23), median DpR was 67%
(Q1-Q3: 56e82%) (Table 4).
DpR correlated with PFS (Spearman Coefficient:
0.53, p < 0.0001) and OS (Spearman Coefficient: 0.51;
p Z 0.0002).
Table 3
Main efficacy results in the WT-KRAS population and according to RAS status.
Pmab-FOLFOX4 Pmab-FOLFIRI P value* Total
% or median (95% CI) % or median (95% CI) Pmab-FOLFOX4
versus Pmab-FOLFIRI
WT-KRAS, N 38 39 77
ORR (not confirmed) 74 (60e88) 67 (52e82) 0.501 70 (60e80)
Surgical resection 45 (29e61) 59 (44e74) 0.211 52 (41e63)
Resection rate (R0 þ R1) 34 (19e49) 46 (31e62) 0.285 40 (29e51)
PFS, months 13 (6e15) 14 (7e16) 0.728 13 (9e15)
OS, months 37 (25e51) 41 (22e52) 0.966 37 (28e49)
WT-RAS, N 27 26 53
ORR (not confirmed) 78 (62e94) 73 (56e90) 0.691 76 (64e87)
Surgical resection 37 (19e55) 69 (52e87) 0.019 53 (39e66)
Resection rate (R0 þ R1) 26 (9e42) 54 (35e73) 0.038 40 (26e53)
PFS, months 13 (6e19) 15 (7e19) 0.307 14 (10e16)
OS, months 39 (27e51) 49 (31e56) 0.824 46 (35e52)
NA Z not achieved; CI Z confidence interval; ORR Z objective response rate (complete response þ partial response); OS Z overall survival;
PFS Z progression-free survival.
Fig. 2. Progression-free survival (top) and overall survival (bottom) in the WT-KRAS population and in the WT-RAS population.
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Table 4
Depth of response and relationship between early tumour shrinkage and progression-free survival and overall survival in the WT-RAS
population.
WT-RAS population Pmab-FOLFOX4 (N Z 27) Pmab-FOLFIRI (N Z 26) Total (N Z 53)
Depth of response
All patients, N 27 24 51
median (Q1, Q3) 47 (32, 71) 48 (42, 64) 48 (32, 67)
Patients with confirmed response, N 13 10 23
median (Q1, Q3) 71 (56, 92) 66 (60, 80) 67 (56, 82)
ETS, N 26 22 48
30%, N (%) 16 (62) 15 (68)y 31 (65)
PFS, months, median (95% CI) 14 (12e27) 19 (6e27) 15 (13e23)
OS, months, median (95% CI) 51 (33 e NE) NE (35 e NE) 60 (45 e NE)
<30%, N (%) 10 (39) 7 (32) 17 (35)
PFS, months, median (95% CI) 5 (1e13) 11 (4e19) 8 (4e14)
OS, months, median (95% CI) 22 (4e37) 31 (6e56) 26 (8e37)
HR-PFS (95% CI) 30% versus <30% (p value) 0.4 (0.2e1.0) (0.050) 0.6 (0.2e1.5) (0.253) 0.5 (0.2e0.9) (0.013)
HR-OS (95% CI) 30% versus <30% (p value) 0.2 (0.1e0.5), (0.002) 0.2 (0.1e0.9), (0.030) 0.2 (0.1e0.5), (0.001)
20%, N (%) 20 (77) 17 (77)z 37 (77)
PFS, months, median (95% CI) 14 (10e27) 15 (6e27) 15 (13e20)
OS, months, median (95% CI) 51 (27 e NE) 52 (35 e NE) 51 (45 e NE)
<20%, N (%) 6 (23) 5 (23) 11 (23)
PFS, months, median (95% CI) 3 (1e13) 8 (4 e NE) 6 (2e13)
OS, months, median (95% CI) 31 (11e39) 8 (6e56) 26 (7e39)
HR-PFS (95% CI) 20% versus <20% (p value) 0.2 (0.1e0.5) (0.001) 0.7 (0.2e2.2) (0.548) 0.4 (0.2e0.8) (0.016)
HR-OS (95% CI) 20% versus <20% (p value) 0.3 (0.1e0.8), (0.021) 0.3 (0.1e1.0), (0.055) 0.3 (0.1e0.6) (0.002)
yp versus Pmab-FOLFOX4 Z 0.632; zp versus Pmab-FOLFOX4 Z 0.977; CI Z confidence interval; DpR Z depth of response; ETS Z early
tumour shrinkage; NE Z non-estimable; PFS Z progression-free survival.
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WT-RAS population
Forty-eight WT-RAS patients had tumour shrinkage
data at week 8. Of them, 65% and 77% had 30% and
20% shrinkage at week 8, respectively, without dif-
ferences between arms (Table 4).
PFS and OS were longer in patients who achieved
ETS  30% and 20% (Table 4 and Fig. 3), although
differences were only significant for most comparisons
in the Pmab-FOLFOX4 arm and all comparisons in the
overall study group.
Resectability rates were numerically higher in pa-
tients achieving ETS  30% (65% versus 35%;
pZ 0.052) and in patients achieving  20% (59% versus
36%; p Z 0.177).
In the WT-RAS population, surgery (n Z 28) was
associated with a longer OS (52 versus 36 months in
patients without surgery [n Z 25]), HR: 0.4 (95% CI:
0.2e0.8; p Z 0.014) (Fig. 3). A comparison between
patients with and without surgery showed that 85% and
77% of patients with surgery had ETS  30% or 20%,
respectively, compared to only 68% and 50% in patients
without surgery.
3.7. Safety
Adverse events in the WT-KRAS population are re-
ported in Table 5. Perioperative safety, induced liver
toxicity and skin toxicity (Supplemental Table S1
(online only)) were similar between arms. Theincidence of diarrhoea (any grade) was similar between
arms (76% Pmab-FOLFOX4; 69% Pmab-FOLFIRI).
Most cases of diarrhoea were grade 1e2. Alopecia was
more frequent with Pmab-FOLFIRI (26% versus 5%).
There were only two infusion reactions in the Pmab-
FOLFOX4 arm (5%). Neutropenia and neuropathy
were the only grade 3/4 AEs that differed significantly
between arms (more frequent with Pmab-FOLFOX4).
Twenty-four (63%) patients treated with Pmab-
FOLFOX4 and 24 (62%) treated with Pmab-FOLFIRI
died. One patient in the Pmab-FOLFOX4 arm (3%)
died due to a treatment-related serious AE (SAE)
necrotising fasciitis.
There were eight more SAEs related to chemotherapy
(five in the Pmab-FOLFOX4 arm in four patients [two
neutropenia events, one diarrhoea, one gastrointestinal
inflammation and one ischaemic stroke] and three in the
Pmab-FOLFIRI arm in two patients [one febrile neu-
tropenia and two diarrhoeas]).
Safety results in the WT-RAS population were
similar, except that no differences in neutropenia and
neuropathy were observed between arms, and that no
deaths related to Pmab and/or chemotherapy were
observed (Supplemental Table S2 (online only)).
4. Discussion
This is the first trial reporting a head-to-head comparison
between Pmab-FOLFOX4 and Pmab-FOLFIRI in a
first-line mCRC setting. Both chemotherapy regimens
have similar activity when used without biologicals [27].
Fig. 3. Overall survival according to early tumour shrinkage 30% or <30% at week 8 (left) and according to surgical resection of liver
metastases (right) in the WT-RAS population.
A. Carrato et al. / European Journal of Cancer 81 (2017) 191e202198Pmab improves outcomes when added to either FOL-
FOX [19] or FOLFIRI [4,20], without compromising
quality of life [28]. In our population of WT-KRAS pa-
tients with LLD, no significant differences were observed
between the two regimens for any of the efficacy out-
comes, in line with previous studies with another anti-
EGFR agent. In the CELIM study (cetuximab-FOL-
FOX versus cetuximab-FOLFIRI in patients with LLD
[30% unresectable] [29]), the OS and PFS in the WT-
KRAS population were similar (OS: 36e42 months
compared with 37e41 months in our study; PFS: 12e12
months versus 13e14 months) [15]. In the CECOG trial
(cetuximab-FOLFOX6 versus cetuximab-FOLFIRI in
WT-KRAS patients with unresectable LLD), the PFS
(9e8 months) and OS (23-20) were shorter, however
>80% of patients had received prior adjuvant treatments,
compared to only 13% in our study [30].Table 5
Summary of adverse events in the WT-KRAS population.
WT-KRAS population Pmab-FO
Grade 3e4, N (%) 32 (84)
Treatment-related Grade 3e4, N (%) 28 (74)
Fatal AEs, N (%) 2 (5)
Treatment-related fatal AEs, N (%) 1 (3)
Serious AE, N (%) 13 (34)
Pmab and/or CT-related serious AE, N (%) 4 (11)
Perioperative AEs, N (%) (in patients with surgery) 4 (24)
Selected grade 3/4a treatment-related adverse events
Neutropenia, N (%) 15 (40)
Conjunctivitis, N (%) 2 (5)
Diarrhoea, N (%) 5 (13)
Asthenia, N (%) 4 (11)
Neuropathy, N (%) 5 (13)
Decreased appetite, N (%) 2 (5)
Induced liver toxicity in patients with surgical resection 17
Any liver complication, N (%) 3 (18)
Sinusoidal dilatation, N (%) 0 (0)
Steatohepatitis, N (%) 1 (6)
Fibrotic changes, N (%) 1 (6)
Hepatocyte necrosis, N (%) 1 (6)
a There was only one grade 5 AE related to Pmab in the Pmab-FOLFOThe extended RAS testing corroborated that this
determination was crucial for identifying patients suit-
able for receiving anti-EGFR antibodies [1,14].
The high response rate observed in the WT-RAS
population allowed a potentially curative resection in
53%of subjects (R0þR1 resectionwas finally achieved in
40%), of whom 75% had initially unresectablemetastases.
The resection ratewas higher in the Pmab-FOLFIRI arm,
but this differencemay be related to the higher proportion
of patients with baseline potentially resectable metasta-
ses. In the Pmab-FOLFOX4 arm, the resection rate was
similar to that observed in the PRIME study (31% in the
subpopulation with LLD treated with Pmab-FOLFOX)
[25]. As in prior studies [11,15], surgery was associated
with an improved survival.
In the PRIME and PEAK studies [25,26], ETS at
week 8 was also an early surrogate marker of improvedLFOX4 N Z 38 Pmab-FOLFIRI N Z 39 P value
30 (77) 0.419
23 (59) 0.172
3 (8) 0.975
0 (0) e
15 (39) 0.698
2 (5) 0.431
5 (22) 0.803
4 (10) 0.003
2 (5) 1.000
4 (10) 0.481
2 (5) 0.431
0 (0) 0.025
0 (0) 0.240
23
6 (26) 0.803
0 (0) e
6 (26) 0.214
0 (0) e
0 (0) e
X4 arm ( necrotising fasciitis).
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resectability rate. Relatively speaking, our results are
also consistent with the exploratory analyses of the
FIRE-3 study of first-line cetuximab versus bev-
acizumab therapy [31], and of other studies of cetux-
imab plus chemotherapy [32]. It is still not clear if the
association between ETS  30% or 20% and increased
PFS or OS is predominantly due to the increased
resectability rate rather than an independent effect. In a
multivariate analysis of the PRIME study, after
adjusting by resection status, the benefit of ETS  30%/
20% was not only observed in resected patients but
also in non-resected patients, suggesting that there could
be an independent effect in this subgroup [25]. In our
study, the median OS in WT-RAS patients with
ETS  30%/20% (60/51 months), despite including
more than one-third of subjects without resection, was
similar to that of resected patients (52 months), which
supports the aforementioned hypothesis.
Depth of response values were consistent with prior
studies (65% in the Pmab-FOLFOX6 of the PEAK
study [26], 54% in the Pmab-FOLFOX4 arm of the
PRIME study [25], 48% for first-line cetuximab-FOL-
FIRI [31]) and higher than the 33% observed with
bevacizumab-FOLFIRI [31]. The differences in assess-
ments beyond RECIST favouring Pmab versus bev-
acizumab, also found in the PEAK study, suggest that
these variables could be more informative than ORR,
which appeared to be similar [26].
Our results indicate a manageable toxicity profile,
consistent with prior studies of Pmab-FOLFOX or
Pmab-FOLFIRI, or with any of these treatments alone
[2,27,33]. It is well known that FOLFIRI is associated
with a higher frequency of alopecia and severe diarrhoea
whereas FOLFOX is associated with a higher frequency
of polyneuropathy [27]. Our results are consistent with
this pattern, except for a similar frequency of diarrhoea,
probably due to a higher incidence in the FOLFOX arm
compared with previous studies [27].
The main limitation was the unblinded surgical re-
view of computed tomography or magnetic resonance
imaging scans, which does not ensure homogeneity in
resectability assessments across centres. However, the
protocol requested the fulfilment of TTD guidelines [34],
which may have reduced subjective evaluations. The fact
that only 11 tumours had RASmutations in exons 3,4 of
KRAS or exons 2,3,4 of NRAS, prevents us from
drawing any conclusions about this subgroup, although
prior Pmab studies clearly show a negative effect on
outcome [1].
In conclusion, similar efficacy and safety results were
obtained in WT-KRAS patients with either first-line
Pmab-FOLFOX4 or Pmab-FOLFIRI, leading both to
high resectability rates. Better outcomes were observed
in the WT-RAS subgroup, without notable differences
between the two regimens. ETS at week 8 was an early
surrogate marker of improved PFS and OS and allowedmore surgeries for hepatic metastases. DpR values were
consistent with prior studies and correlated with PFS
and OS. In patients with WT-RAS mCRC and LLD,
Pmab plus standard first-line treatment chemotherapy
doublet offers the possibility of a rapid and high overall
response rate and a potentially curative hepatic resec-
tion. This strategy in LLD mCRC is also associated with
a favourable long-term survival.
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Study design
This phase II, open-label, randomised (1:1), multicentre,
two-arm parallel study was conducted in 15 Spanish
centres (PLANET Study [TTD-08-04], clinicaltrials.gov
identifier NCT00885885, EudraCT Number: 2008-
006766-28). The ethic committee at each participating
centre approved the study protocol and its amendments.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki. Patients were
included between May 2009 and November 2012. All
patients provided written informed consent.
Patients
Inclusion criteria were: age 18 years; histologically
confirmed WT-KRAS (exon 2) mCRC untreated pa-
tients; LLD (including those patients who had under-
gone complete resection [R0] of the primary tumour at
least 4 weeks before randomisation) fulfilling one of the
following criteria:  4 metastases, at least 1 metastasis
>10 cm in diameter, and metastases technically unre-
sectable, considered by the local hepatic surgeons’
criteria, due to vascular compromise and/or location in
which complete resection was impossible and/or
25e30% of healthy liver would not remain functional
after resection; no major contra-indication to liver sur-
gery; at least one unidimensionally measurable lesion
according to the modified RECIST (mRECIST) criteria
(Version 1.1); recurrence after adjuvant treatment with
5-fluorouracil/folinic acid or capecitabine with or
without radiotherapy with a disease-free interval
(DFI) > 6 months, or after adjuvant treatment with an
oxaliplatin-based regimen with a DFI > than 12
months, or recurrence after surgical treatment and/or
radiotherapy without adjuvant systemic treatment, or de
novo diagnosis; Karnofsky performance status  70%;
adequate bone marrow, hepatic and renal function and
magnesium levels.
Main exclusion criteria were: prior malignant tumour
in the last 5 years, except for a history of basal cell
carcinoma of the skin or preinvasive carcinoma of the
skin; hormonal therapy, chemotherapy, immunotherapy
or experimental or approved proteins/antibodies (e.g.
bevacizumab) received for mCRC treatment; significant
cardiovascular disease including unstable angina ormyocardial infarction within previous 12 months or a
history of ventricular arrhythmia; prior anti-EGFR
therapy or treatment with small molecule EGFR tyro-
sine kinase inhibitors; known positive test for human
immunodeficiency virus infection, hepatitis C virus,
chronic active hepatitis B infection; surgery (not
including diagnostic biopsy or central venous catheter
placement) and/or radiotherapy in the previous 4 weeks.
Study treatment
Patients were randomised to Pmab plus FOLFOX4 or
Pmab plus FOLFIRI. Random assignment was strati-
fied by prior adjuvant FOLFOX therapy and technically
resectable/ unresectable metastases. Preoperative Pmab
(Vectibix, Amgen Europe B.V.) was administered with
FOLFOX4 or FOLFIRI every 14 ds for 4e8 cycles at a
dose of 6 mg/kg, over a 30e90  15 min intravenous
infusion. When surgery became an option, it was per-
formed 4e6 weeks after the last chemotherapy dose.
Patients with stable disease (SD) or who did not achieve
resectability received additional cycles until progressive
disease (PD), unacceptable toxicity or patient with-
drawal. In the event of successful resection (R0 or R1), 6
cycles of adjuvant treatment was administered starting
4e8 weeks after surgery.
If during or after Pmab infusion a reaction occurred,
premedication with acetaminophen/paracetamol and/or
histamine H1 blockers such as diphenhydramine was
administered for subsequent cycles.
Study procedures
Pre-study evaluations included complete medical his-
tory, physical examination (including weight and
height), haematology and biochemistry tests, serum
carcinoembryonic antigen (CEA), electrocardiogram
and radiological imaging of the chest, abdomen, pelvis
and all other sites of disease by computed tomography,
or magnetic resonance imaging if clinically indicated.
KRAS mutation status (exon 2, codons 12 and 13) was
evaluated at each centre while extended RAS mutation
status was analysed at a central laboratory. Mutations
in KRAS exon 3 (at codons 59 and 61) and exon 4 (at
codons 117 and 146); NRAS exon 2 (at codons 12 and
13), exon 3 (at codons 59 and 61) and exon 4 (at codons
117 and 146) were detected by Pyrosequencing using
‘Ras Extension Pyro Kit’ and ‘Therascreen NRAS Pyro
Kit’ (Qiagen, Hilden, Alemania) according to the man-
ufacturer’s recommended protocol.
Tumour response was determined by the mRECIST
criteria (RECIST criteria version 1.1) every 8  1 weeks
until PD or patient withdrawal. Resectability was
assessed every 2 weeks. AEs were collected throughout
the study until 30  3 ds after the last dose of Pmab.
Long-term follow-up visits were performed every 3  1
months after the last safety visit and up to 36 months.
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The primary end-point was the ORR (complete response
[CR]þpartial response [PR]) over the entire treatment
period. Secondary end-points were: resection rate
(R0 þ R1) of liver metastases, time to resection,
progression-free survival (PFS), overall survival (OS),
adverse events (AEs) and perioperative safety. Explor-
atory end-points were: response according to RAS sta-
tus, ETS and DpR in the WT-RAS population and their
relationship with PSF, OS and surgical resection.
Considering a minimum of ORR of 30% (according
to prior results of CRC patients with LLD, treated with
FOLFOX4 or FOLFIRI monotherapy), a sample of 40
subjects per arm were required for correctly selecting the
better treatment when the superior arm was 10% higher,
with at least 80% probability (Simon-Wittes-Ellenberg
design).
The analysis set included all patients who received at
least one dose of Pmab or chemotherapy and followed
up to March 31st, 2015. Efficacy end-points were re-
ported using descriptive statistics, 95% confidence in-
tervals (CI), and KaplaneMeier (KM) plots. Results of
unconfirmed response are reported because liver me-
tastases resection was performed in some patients before
radiological response confirmation. PFS and OS were
calculated as the time from the start of the treatment to
first evidence of clinical progression or death by any
cause. Surgical resection between subgroups defined by
ETS  or <20% or 30% was compared using Chi-square
tests. The effect of ETS, DpR and resection rate on PFS
and OS was assessed with the log-rank test.
AEs were graded based on the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI CTC-AE) version 3.0, with the exception
of Pmab-related skin toxicities, which were graded on
CTC version 3.0 with modifications.
DpR was defined as the maximum percentage change
form baseline in the sum of the longest diameter during
the treatment period prior to surgery. The value was
positive in patients with tumour reduction and negative
in patients with tumour growth. ETS was defined as at
least 20% or 30% tumour decrease in the sum of the
longest diameter compared with baseline at week 8 (2)
post-treatment initiation.
Data analysis was performed using the SAS statis-
tical package for Windows (version 9.4, SAS Institute
Inc., Cary, North Carolina, U.S.).References
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